144 related articles for article (PubMed ID: 17637213)
1. Domperidone is effective in the prevention of rivastigmine-related gastrointestinal disturbances.
Scarzella L; Costanza A; Vastola K
Funct Neurol; 2007; 22(2):101-4. PubMed ID: 17637213
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
4. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
5. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
[TBL] [Abstract][Full Text] [Related]
6. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
7. Strategies to improve tolerability of rivastigmine: a case series.
Venkatesh K; Bullock R; Akbaş A
Curr Med Res Opin; 2007 Jan; 23(1):93-5. PubMed ID: 17257470
[TBL] [Abstract][Full Text] [Related]
8. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Farlow MR; Lilly ML;
BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
[TBL] [Abstract][Full Text] [Related]
10. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
11. [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].
Agüera-Ortiz LF; Ramos-García M; Gobartt AL;
Rev Neurol; 2008 May 1-15; 46(9):517-24. PubMed ID: 18446692
[TBL] [Abstract][Full Text] [Related]
12. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
13. [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
Dartigues JF; Goulley F; Bourdeix I; Péré JJ; Barberger-Gateau P
Rev Neurol (Paris); 2002 Sep; 158(8-9):807-12. PubMed ID: 12386525
[TBL] [Abstract][Full Text] [Related]
14. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
15. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Pregelj P
Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
[TBL] [Abstract][Full Text] [Related]
17. Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
Chiu PY; Dai DE; Hsu HP; Lee C; Lin JJ; Kuo HC; Huang YC; Liu YC; Tsai CP
Clin Drug Investig; 2009; 29(11):729-38. PubMed ID: 19813776
[TBL] [Abstract][Full Text] [Related]
18. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
19. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
[TBL] [Abstract][Full Text] [Related]
20. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.
Jhee SS; Shiovitz T; Hartman RD; Messina J; Anand R; Sramek J; Cutler NR
Clin Neuropharmacol; 2002; 25(2):122-3. PubMed ID: 11981242
[No Abstract] [Full Text] [Related]
[Next] [New Search]